Clinical Trial Update: Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) [Phase 3]

View source ↗

Summary

Phase 3 study assessing the safety and efficacy of ciclesonide in pediatric patients (6-11 years) with seasonal allergic rhinitis. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hay Fever
• Seasonal Allergic Rhinitis

Drugs mentioned

• ciclesonide (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Hay Fever, Seasonal Allergic Rhinitis | Phase 3 | Status: COMPLETED